[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2024,74(3):229-263.
[2] 郑荣寿,陈 茹,韩冰峰,等. 2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志, 2024,46(3):221-231.
[3] Mittelstadt S, Kelemen O, Admard J, et al. Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse[J].Br J Cancer,2023,128(11):2097-2103.
[4] Molina M A, Diatricch L C,Quintana M C, et al. Cervical cancer risk profiling:molecular biomarkers predicting the outcome of hrHPV infection[J]. Expert Rev Mol Diagn, 2020,20(11):1099-1120.
[5] Muresu N, Puci M V, Sotgiu G, et al. Diagnostic accuracy of DNA-methylation in detection of cervical dysplasia:findings from a population-based screening program[J]. Cancers, 2024, 16(11):1986.
[6] Xhaja A, Ahr A, Zeiser I, et al. Two years of cytology and HPV co-testing in germany:initial experience[J].Geburtshilfe Frauenheilkd, 2022, 82(12):1378-1386.
[7] Huang Y, Liang F, Huang J, et al. Improving detection of CIN2+ and CIN3+ lesions:evaluation of E6/E7 mRNA, P16, and Ki-67, individually and in combination[J]. J Med Virol, 2025, 97(5):e70405.
[8] Zhang J, Liu G, Yang D, et al. Age-specific performance of human papillomavirus E6/E7 mRNA assay versus cytology for primary cervical cancer screening and triage:community-based screening in China[J]. Front Cell Infect Microbiol, 2024, 14:1428071.
[9] Nebbioso A, Tambaro F P, Dell’Aversana C, et al. Cancer epigenetics:moving forward[J]. PLoS Genet,2018,14(6):e1007362.
[10] Li N, He Y, Mi P, et al. ZNF582 methylation as a potential biomarker to predict cervical intraepithelial neoplasia type III/worse:a meta-analysis of related studies in Chinese population[J]. Medicine (Baltimore), 2019, 98(6):e14297.
[11] Li N, Hu Y, Zhang X, et al. DNA methylation markers as triage test for the early identification of cervical lesions in a Chinese population[J]. Int J Cancer, 2021, 148(7):1768-1777.
[12] Ding H, Ke Z, Xiao X, et al. A predictive model using six genes DNA methylation markers to identify individuals with high risks of high-grade squamous intraepithelial lesions and cervical cancer[J]. Int J Womens Health, 2025, 17:739-749.
[13] Ji S, Ji N. Methylation sites of human papillomavirus 16 as potential biomarkers for cervical cancer progression[J]. Front Oncol, 2025, 15:1481621.
[14] Xu W, Peng J, Guo C, et al. Rapid and ultra-sensitive early detection of cervical cancer using CRISPR/Cas12-based assay based on methylated SEPT9[J]. Sensor Actuat B-Chem, 2023, 379:133231.
[15] Li N, Song K, Chen H, et al. Advance and challenge of DNA methylation as cancer biomarkers for risk stratification, screening and early detection[J]. J Natl Cancer Cent, 2025, 5(2):108-112.
[16] 赵 敬,杨金豪.中国宫颈癌DNA甲基化标志物的研究进展[J]. 天津医科大学学报, 2021, 27(5):545-548.
[17] 吴若兰,邱丽华. DNA甲基化预测宫颈癌及癌前病变的研究进展[J]. 国际妇产科学杂志, 2023, 50(3):281-285.
[18] Pereira P M, Marques J P, Soares A R, et al. MicroRNA expression variability in human cervical tissues[J].PLoS One,2010,5(7):e11780.
[19] Kotani K, Iwata A, Kukimoto I, et al. Nomogram for predicted probability of cervical cancer and its precursor lesions using miRNA in cervical mucus, HPV genotype and age[J]. Sci Rep, 2022,12(1):16231.
[20] 李旭霞,黄芹芹,温冰一,等.MiRNA联合经阴道彩色多普勒超声诊断宫颈癌的价值[J]. 现代预防医学,2018,45(17):3248-3252.
[21] Parvizi M, Vaezi M, Jeddi F, et al. The role and diagnostic value of deregulated miRNAs in cervical cancer[J]. Discov Oncol, 2025, 16(1):922.
[22] Alimohammadi M, Fooladi A A I, Mafi A, et al. Long noncoding RNAs and HPV-related cervical cancer:uncovering molecular mechanisms and clinical applications[J]. Transl Oncol, 2025, 55:102363.
[23] Naz F, Tariq I, Ali S, et al. The role of long non-coding RNAs (lncRNAs) in female oriented cancers[J]. Cancers,2021, 13(23):6102.
[24] Begliarzade S, Beilerli A, Sufianov A, et al. Long non-coding RNAs as promising biomarkers and therapeutic targets in cervical cancer[J]. Noncoding RNA Res, 2023, 8(2):233-239.
[25] Wu F, Sui Y, Wang Y, et al. Long noncoding RNA SNHG7, a molecular sponge for microrna-485, promotes the aggressive behavior of cervical cancer by regulating PAK4[J].Oncotargets Ther,2020,13:685-699.
[26] Jiao J, Zhang T, Jiao X, et al. Hsa_circ_0000745 promotes cervical cancer by increasing cell proliferation, migration, and invasion[J]. J Cell Physiol, 2020, 235(2):1287-1295.
[27] Dong M, Li P, Xie Y, et al. CircMYBL2 regulates the resistance of cervical cancer cells to paclitaxel via miR-665-dependent regulation of EGFR[J]. Drug Dev Res, 2021, 82(8):1193-1205.
[28] Liu Y, Ai H. Circular RNAs in gynecological cancer:From molecular mechanisms to clinical applications (review)[J]. Oncol Lett, 2025,29(6):291.
[29] Zhao L, Chen X, Zhang Y, et al. The biomarker potential of circPOLD1 and its binding protein YBX1 in cervical carcinogenesis[J]. J Transl Med, 2025, 23(1):506.
[30] Xu Y, Li C, Cheng L, et al. Prognostic and diagnostic value of circRNA expression in cervical cancer:a meta analysis[J]. Front Oncol, 2024, 14:1488040.
[31] Brown J R, Chinnaiyan A M. The potential of circular RNAs as cancer biomarkers[J]. Cancer Epidemiol Biomarkers Prev, 2020, 29(12):2541-2555.
[32] 王小杰,张 梦.血清标志物水平,HPV-DNA分型对早期宫颈癌的诊断价值[J]. 实用癌症杂志,2022,37(4):675-678.
[33] 黄东静.外周血肿瘤异常蛋白联合鳞状细胞癌抗原及薄层液基细胞学检查在宫颈癌筛查中的应用[J]. 川北医学院学报, 2021,36(12):1565-1568.
[34] 周 明,付玉兰,雷 磊,等.血清糖类抗原125, 糖类抗原199 血清铁蛋白在宫颈癌诊断及预后评估中的临床意义[J].癌症进展, 2022,20(15):1559-1562.
[35] Dou H, Sun G, Zhang L.CA242 as a biomarker for pancreatic cancer and other diseases[J].Prog Mol Biol Transl Sci,2019,162(7):229-239.
[36] 要慧萍,杨盼盼,赵勤莉.子宫颈癌中CD3,Ki-67,Bcl-2的表达及其与临床病理特征的关系[J].兰州大学学报(医学版),2022,16(7):50-56.
[37] Liu W, Gong J, Xu H, et al. Good performance of p16/Ki-67dual-stain cytology for detection and post-treatment surveil-lance of high-grade CIN/VAIN in a prospective, cross-sec-tional study[J]. Diagn Cytopathol,2020,48(7):635-644.
[38] Habbani S F, Dowlatshahi S, Lichti N, et al. Protein biomarkers enable sensitive and specific cervical intraepithelial neoplasia (CIN) Ⅱ/Ⅲ+ Detection:one step closer to universal cervical cancer screening[J]. Cancers (Basel). 2025, 17(11):1763.
[39] Habbani S F, Dowlatshahi S, Lichti N, et al. Validation of protein biomarkers for early detection of cervical cancer and squamous intraepithelial lesions[J]. J Clin Oncol, 2025, 43(16 Suppl):e17506.
[40] Jia Y, Zou K, Zou L. Research progress of metabolomics in cervical cancer[J]. Eur J Med Res, 2023, 28(1):586.
[41] Li X, Zhang L, Huang X, et al. High-throughput metabolomics identifies new biomarkers for cervical cancer[J]. Discov Oncol, 2024, 15(1):90.
[42] Nuer-Allornuvor G F, Alolga R N, Liang S, et al. GC-MS-based untargeted plasma metabolomics identifies a 2-biomarker panel for possible diagnosis of precancerous cervical intraepithelial neoplasia stages from cervical cancer[J]. Sci Rep, 2024, 14(1):17649.
[43] Paraskevaidi M, Cameron S, Whelan E, et al. Laser-assisted rapid evaporative ionisation mass spectrometry (LA-REIMS) us a metabolomics platform in cervical cancer screening[J].E Bio Medicine,2020,60:103017.
[44] 方佳琦,卢林丽,薛 鹏,等.人工智能应用于宫颈癌筛查的研究现状[J].中华医学杂志,2023,103(46):3783-3791.
[45] Bao H, Bi H, Zhang X, et al. Artificial intelligence-assisted cytology for detection of cervical intraepithelial neoplasia or invasive cancer:a multicenter, clinical-based, observational study[J]. Gynecol Oncol,2020,159(1):171-178.
[46] Viñals R, Jonnalagedda M, Petignat P, et al. Artificial intelligence-based cervical cancer screening on images taken during visual inspection with acetic acid:a systematic review[J]. Diagnostics (Basel), 2023, 13(5):836.
[47] Peng G, Dong H, Liang T, et al. Diagnosis of cervical precancerous lesions based on multimodal feature changes[J]. Comput Biol Med, 2021, 130:104209.
[48] Kim S, Lee H, Lee S, et al. Role of artificial intelligence interpretation of colposcopic images in cervical cancer screening[J]. Healthcare (Basel), 2022, 10(3):468.
[49] Vargas-Cardona H D, Rodriguez-Lopez M, Arrivillaga M, et al. Artificial intelligence for cervical cancer screening:scoping review, 2009-2022[J].Int J Gynaecol Obstet,2024,165(2):566-578.
[50] 王 陵,冯浚铃,王文文,等.生物统计学在智慧医疗领域的应用进展[J].空军军医大学学报, 2025, 46(5):561-567.